

REMARKS

Claims 1, 2, 4, 5, 10-14, 17-22 and 25-28 remain in the application. Claims 1, 2, 4, 5, 10-14, 17-22 and 25 stand allowed. Claims 26-28 stand rejected. Claim 26 is herein amended.

Rejection under 35 USC §102(e)

Claims 26-28 were rejected as being allegedly anticipated by U.S. Patent No. 6, 812,023 to Lamparski et al. as evidenced by Aswad et al. (J. Pharm Biomed. Anal. 21:1129 (2000)). According to the Examiner, Lamparski teaches use of tumor cell exosomes that contain tumor antigens as agents in a pharmaceutical preparation. Although not explicitly stated, Aswad is apparently cited to show that isoaspartyl peptide bonds are inherent non-enzymatic degradation products. MPEP 2131.01.

While Applicant disagrees with the foundation of the above arguments, in order to expedite prosecution, Applicant herein amends claim 26 to recite, inter alia, a protein selected from the group consisting of tyrosinase, tyrosinase related protein-2 (TRP-2), and combinations thereof. Support for tyrosinase and tyrosinase related protein-2 (TRP-2) can be found on page 11, lines 15-16, and in claim 22. These specific substances are not disclosed or suggested by the references of record. Accordingly, Applicant submits that Lamparski et al. does not anticipate the present invention as now claimed and that this rejection is overcome.

In view of the foregoing, an action allowing all of the claims now in the application and passing this case onto issue is respectfully requested.

If the Examiner has any questions concerning this application, she is encouraged to contact the undersigned attorney.

Please charge any fees due with this response to Deposit Account 23-1665 under Customer Number 27267.

Respectfully submitted,
MARK J. MAMULA

By Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicant

WIGGIN and DANA LLP
One Century Tower
New Haven, CT 06508
Telephone: (203) 498-4400
Fax: (203) 782-2889

Date: 26 Aug 2008

12520\24\2100300.1